Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Arco Lab now holds a 50% stake in Neviton
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
Development services for gene and cell therapies is planned to begin first in 2025
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Expands patient reach to remotest towns by furthering investment in GoApptiv
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Subscribe To Our Newsletter & Stay Updated
